** This advocacy campaign ran from November 2020 to January 2021**

 

The ISF would like to thank the hundreds of people who supported our work to advocate for the availability for Dupilumab in Ireland.  We would also like to extend our thanks to TDs and policy makers who supported the eczema and dermatology patient community in raising awareness of this important issue.

In February 2021, the HSE’s Executive Management Team supported reimbursement of this treatment.  Following this decision the ISF paused our campaign pending developments currently underway.  We expect patients struggling to manage treatment-resistant atopic eczema to be able to access this new treatment, through hospital dermatology clinics, by the summer 2021.

Please see our statements below for more information about this campaign.

February 5, 2021

Follow access-to-dupilumab advocacy developments

The ISF has been working to raise awareness and to secure access to dupilumab, follow developments below:

 

Find out more about ISF advocacy click here.  If you have questions about dupilumab or this campaign please e-mail us at info@irishskin.ie

 

You can also monitor the progress on the HSE’s assessment of dupilumab by following this link: http://www.ncpe.ie/drugs/dupilumab-dupixent/

This webpage and campaign is an independent advocacy initiative of the Irish Skin Foundation, it has been not supported or sponsored by Foundation Partners or corporate donations.  


For more information about atopic dermatitis and eczema, visit our main eczema page here.  If you need help or guidance about managing your eczema, contact the ISF Helpline here.

Share: